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Abstract
Background: Dietary lipids or pharmacologic modulation of lipid metabolism are potential therapeutic strategies in
inflammatory bowel disease (IBD). Therefore, we analysed alterations of bioactive lipids in experimental models of colitis
and examined the functional consequence of the second messenger ceramide in inflammatory pathways leading to tissue
destruction.
Methodology/Principal Findings: Chronic colitis was induced by dextran-sulphate-sodium (DSS) or transfer of CD4
+CD62L
+
cells into RAG1
2/2-mice. Lipid content of isolated murine intestinal epithelial cells (IEC) was analysed by tandem mass
spectrometry. Concentrations of MMP-1 in supernatants of Caco-2-IEC and human intestinal fibroblasts from patients with
ulcerative colitis were determined by ELISA. Imipramine was used for pharmacologic inhibition of acid sphingomyelinase
(ASM). Ceramide increased by 71% in chronic DSS–induced colitis and by 159% in the transfer model of colitis.
Lysophosphatidylcholine (LPC) decreased by 22% in both models. No changes were detected for phosphatidylcholine.
Generation of ceramide by exogenous SMase increased MMP-1-protein production of Caco-2-IEC up to 7-fold. Inhibition of
ASM completely abolished the induction of MMP-1 by TNF or IL-1b in Caco-2-IEC and human intestinal fibroblasts.
Conclusions/Significance: Mucosal inflammation leads to accumulation of ceramide and decrease of LPC in the intestinal
epithelium. One aspect of ceramide generation is an increase of MMP-1. Induction of MMP-1 by TNF or IL-1b is completely
blocked by inhibition of ASM with imipramine. Therefore, inhibition of ASM may offer a treatment strategy to reduce MMP-1
expression and tissue destruction in inflammatory conditions.
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Introduction
Many signalling molecules involved in the pathogenesis of
inflammatory bowel disease (IBD) such as tumor necrosis factor
(TNF) or interleukin-1 beta (IL-1b) cause alterations of the lipid
composition in the cell membrane by activation of various
phospholipases, sphingomyelinases and other lipid modifying
enzymes [1–4]. Previous reports demonstrated therapeutic effects
of lipid administration [5–7] or inhibition of lipid modifying
enzymes [8] for the treatment of intestinal inflammation.
Ceramide or lysophosphatidylcholine play key roles as second
messengers for intracellular signalling with the potential to control
inflammatory responses.
Ceramide is generated by de novo synthesis or hydrolysis of
plasma membrane sphingomyelin via the action of sphingomy-
elinases (SMases). SMases are characterized by their optimal pH
and are divided accordingly into acid, neutral and basic
sphingomyelinase species. The acid sphingomyelinase (ASM)
contributes to lysosomal sphingomyelin turnover and is also
secreted upon cellular treatment with inflammatory stimuli [9,10].
Ceramide has been implicated in a variety of cellular processes
from cell growth, differentiation and gene transcription to cell
death [11,12]. Ceramide seems to play a central role for the
pathophysiology of several common diseases [9] and is a key
mediator for apoptosis, cellular invasion of bacteria and viruses,
radiation- and chemotherapeutic responses, heat damage, UVA-
light and ischemia-reperfusion injury [13]. Increasing evidence
suggests implications of SMases in the development of colon
cancer or IBD [13,14]. Inhibition of ASM has been shown to
protect from DSS-induced colitis in mice [15]. The authors
suggested that the protective effect of ASM-inhibition was
mediated by the suppression of cytokine production from
macrophages in response to LPS. Unfortunately, the response of
intestinal epithelial cells (IEC) and fibroblasts has not been
investigated, although these cells may well contribute to the
protective effects of ASM-inhibition.
Phosphatidylcholine (PC) is the main phospholipid component
of eukaryotic cells. Instillation of PC and phosphatidylinositol have
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The formation of strictures in a rat model of colitis was also
prevented by oral supplementation of polyunsaturated PC,
possibly by stimulation of collagen breakdown [6]. The studies
by Stremmel et al focused on the content of PC in mucus layers as
the possible culprit for uncontrolled inflammation of the intestine
[7,16] which may be prevented by administration of PC.
Nevertheless, in vitro studies revealed that exogenously added
PC is also integrated into the cells and has anti-inflammatory
properties in Caco-2 intestinal epithelial cells, especially in
response to TNF [17]. Lysophosphatidylcholine (LPC) is a
metabolic product of PC and displays inflammatory activity.
Biosynthesis is regulated by PLA2 that catalyzes PC hydrolysis
[18]. LPC acts as a chemotactic factor for monocytes and T cells
and displays proinflammatory properties even at nanomolar
concentrations [19]. Phosphatidylethanolamine (PE) and plasma-
logenes (PE-pl) serve as precursors for lipoxygenases, thereby
contributing to immune-regulatory activities [20].
Excessively produced Matrix Metalloproteinase-1 (MMP-1) is
believed to damage the colonic mucosa in patients with ulcerative
colitis [21,22]. MMP-1, also called interstitial collagenase, belongs
to a family of zinc-dependent metalloendopeptidases collectively
capable of degrading essentially all extracellular matrix (ECM)
components [23,24]. Most of the MMPs are secreted as
proenzymes and require proteolytic cleavage for activation [25].
Activity of MMPs is further regulated by a group of endogenous
proteins, so called tissue inhibitors of metalloproteinases (TIMPs)
that bind to active and alternative sites of activated MMPs [26].
The balance of activated MMPs and TIMPs is crucial to maintain
tissue allostasis. Excessive production or activation of MMPs
results in uncontrolled degradation of ECM [25,27,28]. MMP-1 is
increased upon stimulation with inflammatory cytokines such as
IL-1b or TNF [29], ionizing radiation [30] or UVA irradiation
[31]. Expression of MMP-1 has been linked with ceramide
metabolism via activation of extracellular signal-regulated and
stress-activated protein kinase pathways [32,33] but the relevance
of this association for the mentioned stimuli and the involvement
of endogenous SMases remain to be determined. ASM-activating
cytokines and stimuli greatly overlap with the stimulatory
processes which increase MMP-1. Therefore, we investigated the
effects of these stimuli on MMP-1 production in IEC and intestinal
fibroblasts.
To determine the occurring lipid alterations in intestinal
inflammation, we quantified bioactive lipids in two murine models
of chronic colitis. The increase of ceramide was linked with the
secretion of MMP-1. Exogenous SMase produced high levels of
MMP-1 in Caco-2 IEC and induction of MMP-1 by TNF or IL-
1b was completely abrogated by inhibition of ASM with
imipramine.
Materials and Methods
Mice
Female Balb/c (Harlan Winkelmann, Borchen, Germany) and
RAG1
2/2 mice (Taconic, USA) weighing 19–22 g were
individually housed in standard polycarbonate mouse cages for
at least two weeks before the start of the experiment. All mice were
kept under standard laboratory conditions (12-h light/dark cycle,
2262uC; 6065% humidity). All experimental protocols were
approved by the Committee on Animal Health and Care of the
local government (AZ 621-2531.1-08/04), and conformed to
international guidelines on the ethical use of animals. All efforts
were made to minimize the number of animals used and their
suffering.
Cells and reagents
Caco-2 cells were maintained in Dulbecco’s minimum essential
medium (DMEM), supplemented with 10% fetal calf serum (FCS),
1% penicillin/streptomycin, 1% non-essential amino acids and
1% sodium pyruvate in an atmosphere containing 10% CO2 at
37uC. FCS was inactivated for 1h, 50uC. Isolation and cultivation
of fibroblasts is described below. For quantification of MMP-1
protein by ELISA, experiments were performed without FCS. To
avoid prestimulation by serum withdrawal, primary fibroblasts
were maintained in medium with 0.5% FCS prior to stimulation
with TNF. Sphingomyelinase from staphylococcus aureus and
imipramine were purchased from Sigma-Aldrich, Taufkirchen,
Germany. IL-1b, TNF and MMP-1 ELISA were purchased from
R&D Systems, Wiesbaden, Germany.
Isolation of human fibroblasts from patients
Human fibroblasts were isolated from colonic sections of patients
with ulcerative colitis or sections of non-IBD patients without
inflammation. Fibroblasts were isolated and cultured as previously
described [34,35]. In brief, the mucosa from surgical patients was
cut into 1-mm pieces and epithelial cells were removed in Hank’s
Balanced Salt Solution (HBSS) without Ca
2+ and Mg
2+ (PAA,
Co ¨lbe, Germany) with 2mM ethylenediaminetetraacetic acid
(EDTA) (Sigma-Aldrich, Taufkirchen, Germany). The remaining
tissue was digested for 30 min at 37uC in phosphate-buffered saline
(PBS, Gibco, Karlsruhe, Germany) containing 1 mg/ml collage-
nase I (Sigma-Aldrich), 0.3mg/ml DNase I (Roche, Mannheim,
Germany), and 2mg/ml hyaluronidase (Sigma-Aldrich). Isolated
cells were washed with DMEM containing 20% FCS and cultured
in 25-cm
2 culture flasks (Costar, Bodenheim, Germany) with
DMEM containing 10% FCS, penicillin (100IU/ml), streptomycin
(100 mg/ml), ciprofloxacin (8 mg/ml), gentamycin (50 mg/ml), and
amphotericin B (1 mg/ml). Non-adherent cells were removed by
subsequent changes of medium.
Antibodies
The following antibodies were used for flow cytometry (FACS)
analysis: Rat anti-mouse G8.8 (Ep-CAM) antibody was a kind gift
by Dr. U. Strauch, Regensburg, Germany. Fluorescein (FITC)
conjugated F(ab’)2 fragment goat anti-rat IgG were from Jackson
ImmunoResearch, Suffolk, UK.
MMP-1 ELISA
For detection of MMP-1, fibroblasts and Caco-2 cells were
seeded in 12-well plates. Experiments were performed in medium
without FCS or 0.5% FCS in the case of stimulation by TNF. Cells
were incubated with the indicated substances. For pharmacologic
inhibition of ASM imipramine (30 mM) was used. Concentration
of MMP-1 in supernatants was determined by ELISA (R&D
Systems). All measurements were performed in duplicate.
Dextran sulphate sodium (DSS) induced chronic colitis
For induction of chronic colitis mice received 3% DSS (MP
Biomedicals, Illkirch, France) in drinking water for 7 days, as
described previously [36]. Each cycle consisted of 3% DSS in
drinking water for 7 days, followed by a 7 days interval with
normal drinking water. Mice were failed to 4 cycles and were used
for the experimental treatment 4 weeks after completion of the last
cycle.
CD4
+CD62L
+ T cell transfer model of colitis
Splenic CD4
+CD62L
+ T cells from Balb/c mice were isolated
as described previously [37,38]. In brief, CD4
+CD62L
+ T cells
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CD4
+CD62L
+ T Cell isolation kit with immunomagnetic
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
CD4
+CD62L
+ T cells (0.25610
6) were resuspended in 200 mlo f
sterile phosphate buffered saline (PBS) and injected intraperitone-
ally in recipient RAG1
2/2 deficient mice. Colitis activity was
monitored by weight changes and histological analysis. After 6–8
weeks mice were used for experiments.
Histological score
For the histological analyses cross sections of the colon were
fixed in 4% formalin and the tissue was embedded in paraffin,
sliced in sections of 2 mm thickness and stained with haematoxylin-
eosin and scored as described [36,39]. The predominant feature of
microscopic inflammation in colitis is the mononuclear cell
infiltration limited to the mucosa and the consecutive mucosal
damage with loss of goblet cells and loss of crypts. Both features
were independently graded from 0 to 4 and the mean score was
noted. The total histological score represents the sum of the
epithelium and infiltration score and ranges from 0 to 8.
Affymetrix gene array
First, Caco-2 cells (6675cm
2 flask) were stimulated with exogenous
SMase (0.1 U/ml) for 6h and 24h. After incubation, cells were
isolated with RNeasy Mini Kit (Qiagen, Hilden, Germany). Gene
expression profiles were determined as described before [40] using
Affymetrix HGU133A and HGU133B GeneChips (Affymetrix,
Santa Clara, CA), which cover 22,283 annotated human genes
(U133A) and more than 33,000 human EST sequences (U133B).
Caco-2 RNA stimulated with exogenous SMase (6h and 24h) was
used for pooling to generate complementary RNA (cRNA). The
remaining amount of RNA was used for real-time RT-PCR
validation in single samples. 10 mg of pooled total RNA was
converted to complementary DNA (cDNA) using a T7-oligo-d(T)24
primer and SuperScript reverse transcriptase (Invitrogen, Carlsbad,
CA, USA). Second-strand cDNA synthesis and blunt ending was
performed using T4 DNA polymerase, Escherichia coli DNA ligase,
and T4 polynucleotide kinase. Following phenol-chloroform extrac-
tion, cDNA was used for in vitro transcription reaction using the T7
BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnos-
tics, Farmingdale, NY, USA) to produce biotinylated cRNA.
Thereafter, the labeled cRNA was purified using RNeasy Mini Kit
columns (Qiagen) and fragmented by incubation at 94uCf o r
30 minutes. Fragmentation was checked by microcapillary electro-
phoresis on an Agilent 2100 bioanalyzer, and 30 mg of biotinylated
cRNAs was split into 2 parts and hybridized to U133A and U133B
GeneChips,respectively,for16 hours at 45uC with constant rotation.
Microarray was processed in an Affymetrix GeneChip Fluidics
Station 400. Following staining with streptavidin-conjugated phyco-
erythrin and washing cycles, the microarrays were scanned using the
GeneArray Scanner (Agilent Technologies). Expression signals for
each transcript and comparisons between different samples were
calculated with the Affymetrix GeneChip software MAS5.0 and
Microsoft Excel (Microsoft Corp., Redmond, WA) [40].
Tandem mass spectrometry
Intestinal epithelial cells (IECs) were isolated from mice colon as
previous described [41]. After isolation, cells were washed with ice-
cold PBS twice. Samples were prepared by addition of 500 ml ice-
cold H2O with 0.2% SDS, followed by addition of 500 mlH 2O.
Lipids were quantified by electrospray ionization tandem mass
spectrometry (ESI-MS/MS) in positive ion mode as described
previously [42,43]. Samples were quantified by direct flow
injection analysis using the analytical setup and the data analysis
algorithms described by Liebisch et al. [42]. A parent ion scan of
m/z 184 specific for phosphocholine containing lipids was used for
phosphatidylcholine, sphingomyelin and lysophosphatidylcholine.
Neutral loss scans of m/z 141 and m/z 185 were used for
phosphatidylethanolamine and phosphatidylserine, respectively.
PE-based plasmalogens (PE-pl) were analysed by fragment ions of
m/z 364, 380 and 382 for PE p16:0, p18:1 and p18:0 species,
respectively. Ceramide was analysed using N-heptadecanoyl-
sphingosine as internal standard. Free cholesterol (FC) and CE
species were determined after selective acetylation of FC.
Quantification was achieved by calibration lines generated by
addition of naturally occurring lipid species to cell homogenates.
Statistical analysis
Data are shown using vertical Box-Whisker plots (25% and 75%
values), generated in the basic module of the programs SigmaPlot/
SigmaStat. Statistical analysis was performed by student’s t-test
or Mann-Whitney U-test, with p,0.05 considered statistically
significant. Data are given as means 6 SEM.
Results
Lipid alterations in chronic DSS–induced colitis and
CD4
+CD62L
+ transfer model of colitis: increase of
ceramide, decrease of lysophosphatidylcholine
To identify inflammation induced lipid alterations, we first
analysed the occurring changes of bioactive lipids in experimental
models of chronic colitis by tandem mass spectrometry.
Isolated colonic IEC of mice suffering from chronic DSS-
induced colitis showed the following lipid alterations when
compared to control (Figure 1A–1C):
Ceramide increased by 71% (Figure 1A). In contrast, lysophos-
phatidylcholine (LPC) decreased by 22% (Figure 1A). Levels of
phosphatidylcholine remained constant (Figure 1B). Free choles-
terol (Figure 1B), Sphingomyelin (Figure 1C) and phosphatidyl-
ethanolamine (Figure 1C) declined. Plasmalogenes (Figure 1C)
increased. Histological score of mice with DSS-induced colitis
versus control is shown in Figure 1D. To exclude contamination of
IEC by other cells, isolated cells were stained with FITC-coupled
anti-G8.8 antibodies, specific for epithelial cells [44]. Flow
cytometry revealed that more than 93% of isolated cells were of
epithelial origin (Figure 1E), indicating a good purification of IEC
without relevant numbers of other mucosal cells.
Colonic IEC from mice with chronic colitis by transfer of
CD4
+CD62L
+ cells displayed the following changes (Figure 2A
and 2B):
Ceramide increased by 159% (Figure 2A). In contrast,
lysophosphatidylcholine (LPC) decreased by 22% (Figure 2A).
Levels of phosphatidylcholine (Figure 2B) and free cholesterol
(Figure 2B) remained constant. Histological score of mice in
CD4
+CD62L
+ transfer model of colitis was higher compared to
control mice (Figure 2C).
Increased expression of MMP-1- and MMP-10-mRNA by
exogenous SMase in Caco-2 intestinal epithelial cells (IEC)
Based on the differences found in chronic colitis, we examined
the effects of ceramide generation in IEC by affymetrix gene array
analysis. Therefore the colorectal cancer cell line Caco-2 was
incubated with exogenous SMase (0.1 U/ml) to identify ceramide
induced effects possibly involved in IBD pathophysiology. The
experiments revealed a fast and robust increase of MMP-1 and
MMP-10 (Figure 3). The induction of MMP-10 was not further
investigated.
Ceramide and Colitis
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production in Caco-2 cells
MMP-1 protein production upon generation of ceramide was
confirmed by quantification of active MMP-1 by ELISA.
Supernatants of Caco-2 cells were analysed 24h after incubation
with exogenous SMase (Figure 4). Exogenous SMase led to a dose-
dependent increase of MMP-1 with a 3.1-fold increase at
concentrations as low as 0.005 U/ml and maximal increase at a
concentration of 0.125 U/ml (Figure 4).
Inhibition of acid sphingomyelinase (ASM) by imipramine
completely abrogates the induction of MMP-1 by IL-1b
and TNF
MMP-1 production in Caco-2 cells was induced by stimulation
of cells with the ASM-activating inflammatory cytokines TNF
(10ng/ml) or IL-1b (1ng/ml). For inhibition of acid sphingomy-
elinase, cells were incubated with imipramine (30 mM). Imipra-
mine causes proteolytic degradation of ASM [45–47] and was
therefore added to the cells 30 minutes prior to stimulation. IL-1b
induced a 2.9-fold (60.07) secretion of MMP-1 (Figure 5A) which
was completely absent in cells treated with imipramine (Figure 5A).
MMP-1 increased by 2.5-fold (60.1) after stimulation with TNF
(Figure 5A) while treatment of the cells with imipramine
completely blocked this increase (Figure 5A). These results
demonstrate ASM-dependence of IL-1b and TNF for MMP-1
induction in the colon epithelial cell line.
Because fibroblasts essentially contribute to MMP-1 production
in IBD, we assessed the occurring changes of MMP-1 in primary
intestinal fibroblasts upon stimulation with the ASM-activating
inflammatory cytokines TNF and IL-1b. Again, we used
imipramine for pharmacologic inhibition of ASM, to analyze the
contribution of ASM for production of MMP-1. Induction of
MMP-1 by IL-1b or TNF was completely abolished by
imipramine in all the investigated primary fibroblasts, including
three different sets from healthy control (CO I, CO II, CO III) and
Figure 1. Increase of ceramide and decrease of LPC in chronic DSS-induced colitis. (A–C) Lipid analysis of isolated colonic IEC by tandem
mass spectrometry (control n=12, 3% DSS n=10). (A) Proportion of ceramide and LPC of analysed lipids. (B) Proportion of PC and FC of analysed
lipids. (C) Proportion of SM, PE and PE-pl of analysed lipids. (D) Histological score. (E) Surface expression of epithelial cell marker, determined by flow
cytometry after staining of the cells with FITC-labelled anti G8.8 antibodies. (**p,0.01, ***p,0.001)
doi:10.1371/journal.pone.0007197.g001
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+CD62L
+ cells in RAG-1
2/2 mice. (A,B) Lipid
analysisofisolatedcolonicIECbytandemmassspectrometry(controln=3,CD4
+CD62L
+n=6).(A)ProportionofceramideandLPCofanalysedlipids.(B)
Proportion of PC and FC of analysed lipids. (C) Histological score. (*p,0.05)
doi:10.1371/journal.pone.0007197.g002
Figure 3. Induction of MMP-1- and MMP-10-mRNA in the
intestinal epithelial cell lineCaco-2after generationof ceramide
by exogenous SMase (0,1U/ml), as determined by affymetrix
gene array analysis. Data are presented as relative increase after 6h
and 24h in comparison to untreated control. (n=4; ***p,0.001)
doi:10.1371/journal.pone.0007197.g003
Figure 4. MMP-1 protein expression of Caco-2 IEC is induced
by exogenous SMase. Cells were incubated with increasing doses of
exogenous SMase. Concentration of active MMP-1 was determined in
supernatants after 24h by ELISA. (*p,0.05, **p,0.01; n=6)
doi:10.1371/journal.pone.0007197.g004
Ceramide and Colitis
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III) (Figure 5B and 5C). Upon stimulation with IL-1b (1ng/ml) or
TNF (10ng/ml), control fibroblasts increased MMP-1 secretion
(Figure 5B). Treatment with imipramine abrogated the effect of
IL-1b or TNF with significant inhibition when compared to cells
with IL-1b or TNF only. Fibroblasts from patients with ulcerative
colitis also increased MMP-1 while treatment with imipramine
resulted in MMP-1-levels with significant inhibition when
compared to cells with IL-1b or TNF only (Figure 5C).
It is important to note that complete serum withdrawal
prestimulated the primary fibroblasts with only little response to
TNF. Therefore 0.5% FCS was maintained to avoid prestimula-
tion of primary fibroblasts by serum withdrawal.
Discussion
In the present study, we analysed the levels of bioactive lipids in
two models of chronic colitis and identified ceramide as a novel
second messenger for disease pathology in IBD. We demonstrate
that generation of ceramide and activity of acid sphingomyelinase
are required for the production of MMP-1, which is believed to
damagethecolonicmucosainpatients withulcerativecolitis[21,22].
Using electrospray ionization tandem mass spectrometry (ESI-
MS/MS), we found increased concentrations of ceramide in ex
vivo preparations of murine intestinal epithelial cells, and decrease
of the degradation product of PC lysophosphatidylcholine.
Increased levels of ceramide result from upregulated sphingomy-
elin breakdown by sphingomyelinases and/or reduced degrada-
tion of ceramide by acid ceramidase. To determine the role of the
second messenger ceramide, generated by sphingomyelin break-
down, the intestinal epithelial cell line Caco-2 and primary
intestinal fibroblasts from patients with ulcerative colitis or healthy
controls were challenged with exogenous SMase or the inflam-
matory cytokines IL-1b and TNF to induce ceramide generation.
Affymetrix gene array analysis of Caco-2 IEC revealed dramatic
increases of MMP-1 and MMP-10 after generation of ceramide by
exogenous SMase. Dose dependent induction of MMP-1 protein
expression in Caco-2 IEC upon incubation with exogenous SMase
was verified by ELISA. To our knowledge, this is the first
description of MMP-1 induction by ceramide in epithelial cells
with possible implications for the understanding and treatment of
tumor invasion and metastasis. After all, fibroblasts need an
inflammatory stimulus in addition to exogenous SMase to induce
MMP-1 expression. This regulation is lost in the epithelial cancer
Figure 5. Pharmacological inhibition of ASM by imipramine abrogates induction of MMP-1 by IL-1b and TNF. Concentration of MMP-1
in supernatants was determined after 24h by ELISA. (A) Stimulation of Caco-2 IEC with IL-1b or TNF 6 imipramine (n=5). (B) Stimulation of primary
control fibroblasts CO I (n=12), CO II (n=9) and CO III (n=10) with IL-1b or TNF 6 imipramine. (C) Stimulation of primary fibroblasts from patients
with ulcerative colitis UC I (n=10), UC II (n=6) and UC III (n=6) with IL-1b or TNF 6 imipramine. (*p,0.05, **p,0.01; ***p,0.001)
doi:10.1371/journal.pone.0007197.g005
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generation of ceramide by exogenous SMase alone.
Using acid sphingomyelinase (ASM)-deficient fibroblasts as a
genetic model, we have previously shown ASM-dependent
induction of MMP-1 by IL-1b [48]. To elucidate the role of
sphingomyelin degradation by ASM for MMP-1-induction in IEC
and intestinal fibroblasts, activation of ASM was pharmacologi-
cally inhibited by imipramine. Imipramine interferes with
ceramide signalling, particularly by inhibition of ASM [45–47].
TNF and IL-1b, which are known to induce MMP-1 expression as
well as to activate ASM, served to evaluate the relevance of ASM-
mediated MMP-1-induction [49,50]. Importantly, inhibition of
ASM by imipramine completely abrogated the induction of MMP-
1 after stimulation with TNF or IL-1b. These data suggest that
generation of ceramide by ASM upon TNF or IL-1b augments
intestinal tissue destruction by increase of MMP-1 production
which can be prevented by inhibition of ASM. Unfortunately,
rodents do not express MMP-1. Therefore, we were not able to
explore the effects of ASM-inhibition on MMP-1 expression in our
murine models of colitis.
Another consequence of ceramide accumulation may be an
increase of cell death and susceptibility to infection, which was
demonstrated in a very recent publication by Teichgra ¨ber et al,
employing an animal model of cystic fibrosis [51]. As shown by
Sakata et al., ASM also contributes to increased secretion of
inflammatory cytokines in a murine model of experimental colitis
[8]. Alteration of membrane fluidity by ceramide has also been
shown to affect permeability of IEC [52] and the function of
diverse ion channels [53,54], which may also contribute to
extensive loss of fluids and increase of IEC apoptosis in IBD. All of
the effects mentioned above may be prevented by inhibition of
ASM. Positive effects of imipramine on the clinical course of UC
were shown by Esmaeili et al [55]. In view of our results, part of
these effects are possibly explained by reduced production of
MMP-1.
To address the question of PC administration, which has been
reported to be protective in ulcerative colitis [5–7], we also
compared levels of PC and its degradation product LPC. We did
not find direct evidence for a deficiency of PC in intestinal
epithelial cells but concentrations of LPC were much lower in
inflamed colonic epithelium. This decrease is suggestive of a
regulatory response of the mucosa to reduce inflammation, by
reduction of inflammatory cytokines like IL-1b [56] and less
recruitment of monocytes and T cells [19]. Therefore, the
decrease of LPC most likely represents a mechanism of the
intestinal mucosa for resolution of inflammation.
In summary, our data demonstrate increased levels of ceramide
in experimental colitis. The results indicate a role of ceramide for
the pathogenesis of IBD by regulation of MMP-1 expression.
Pharmacologic inhibition of ASM by imipramine completely
abrogates the induction of MMP-1 upon TNF or IL-1b.
Therefore, inhibition of ASM may be a possible treatment
strategy for intestinal inflammation, in particular ulcerative colitis.
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